Summit Therapeutics

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Summit Therapeutics reports strong financials and strategic Akeso partnership

Summit Therapeutics showcased strong financials, promising clinical trial results, and a strategic partnership with Akeso for ivonescimab, positioning the company for growth.
While facing challenges around licensing agreements and international trial data acceptance, Summit's focus on oncology and global collaborations presents opportunities for future success.
With a solid financial foundation, innovative pipeline, and strategic vision, Summit is well-positioned to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Summit Therapeutics secures $5B deal for ivonescimab, shifts to oncology

Summit Therapeutics made a strategic move with a $5 billion transaction for ivonescimab, signaling a shift towards oncology-focused R&D.
While challenges exist in transitioning away from anti-infectives, Summit's strong financial position and Phase III progress offer promising opportunities.
The company's commitment to innovative therapies and strategic partnerships sets the stage for potential growth and market success.

Summit Therapeutics reports stable finances and progress in Phase III trials

Summit Therapeutics showcased resilience with a strong cash position despite reporting a net loss in Q2 2023.
The company's progress in Phase III trials and positive patient response data offer promise for future growth.
While facing challenges in trial execution and financial pressures, Summit has opportunities to advance its pipeline and attract investor support.

Summit Therapeutics advances ivonescimab in Q3 with strong financials

Summit Therapeutics is making significant strides in advancing ivonescimab for solid tumors, supported by strong financials and strategic partnerships. While facing challenges in differentiation and competitive landscape, the company is well-positioned to seize opportunities for growth and innovation. With a focus on operational excellence and clinical trial progress, Summit remains poised for future success.

Summit Therapeutics excels in Q4 with Ivonescimab progress and challenges

Summit Therapeutics showcased strong performance and financial stability, driven by advancements in Ivonescimab's trials and partnerships.
While facing challenges such as upcoming regulatory actions and timeline constraints, the company remains poised to leverage opportunities for market differentiation and growth.

Summit Therapeutics advances ivonescimab in oncology, eyes Phase III data

Summit Therapeutics made significant progress in Q1 2024, bolstered by strong financials and strategic collaborations. The company's focus on ivonescimab's potential in oncology, along with upcoming data releases, positions it for future success. Managing R&D expenses and leveraging key partnerships will be critical for sustained growth.

Summit Therapeutics advances ivonescimab with strong financial backing and collaborations

Summit Therapeutics made significant progress in clinical trials and regulatory milestones for ivonescimab, supported by strong financials and strategic collaborations.
While facing challenges in data disclosure and operational management, the company has opportunities to drive growth through further trial success and partnerships.
Overall, Summit Therapeutics is well-positioned to capitalize on its strengths and navigate challenges to unlock future opportunities in the competitive biopharmaceutical landscape.
Investors should monitor the company's continued progress in trials, partnerships, and financial management for insights into its long-term growth potential.

Summit Therapeutics advances ivonescimab with strong financial backing and global trials

Summit Therapeutics demonstrated strong performance in advancing ivonescimab, supported by robust financial management and operational efficiency.
While facing challenges in regulatory uncertainties and managing expenses, the company has opportunities to leverage positive trial outcomes and strategic expansions.
Overall, Summit Therapeutics' progress with ivonescimab presents a promising outlook for accelerated development and market growth in diverse tumor settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics (SMMT 8.36%) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340% since January 2023.

Where Will Summit Therapeutics Be in 5 Years?

Moderna

Uber

A five-bagger in only five years? Any investor would love to buy such a stock.

3 Stocks That Could Turn $1,000 into $5,000 by 2030

BioNTech SE

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

Viking Therapeutics

It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (VKTX -1.75%) and Summit Therapeutics (SMMT -0.22%) more than doubled in 2024.

2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street

AppLovin Corp

MicroStrategy Incorporated

Normally, you might expect to achieve significant gains from stocks if you invest in them for years, perhaps decades. But given how hot the stock market has been this year, some stocks have produced life-changing returns in much shorter time frames.

Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee.

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.

Here's Why Summit Therapeutics Stock Price Rose 6% on Friday

Summit Therapeutics (SMMT 5.82%) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors snapped it up to push its price nearly 6% higher across the day's trading session.

Why Summit Therapeutics Stock Rocketed 6% Higher on Friday

Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC.  The FDA has fast tracked the HARMONi trial. Positive Phase III results for ivonescimab versus KEYTRUDA in first-line NSCLC are promising, but registration in the US will require completion of HARMONI-7, which has just begun recruiting. Top-line data from the HARMONi trial is expected in mid-2025, potentially leading to FDA approval with complete enrollment as of Q3.

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Do you ever wonder what America's wealthiest stock traders are buying and selling? Thanks to the Securities and Exchange Commission, you don't have to.

Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific antibody, ivonescimab, at the Evercore HealthCONx Conference on Tuesday December 3, 2024 at 8:4.

Summit Therapeutics to Present at Upcoming Investor Conferences

CRISPR Therapeutics

3 Monster Stocks in the Making

Merck

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug. The post Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics appeared first on Investor's Business Daily.

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

If you're patient, these businesses have a lot of promising projects in the works.

2 Hot Biopharma Stocks to Buy and Hold for 5 Years

A cancer drug has vast potential for the company, says a pundit newly following it.

Why Summit Therapeutics Stock Was a Winner Today

JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones.

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

Summit Therapeutics Inc. NASDAQ: SMMT is a development-stage biotech company specializing in novel therapies for oncology and infectious diseases. Their leading drug candidate is Ivonescimab, an immunotherapy treatment being tested on non-small cell lung cancer (NSCLC).

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?

AstraZeneca

Exelixis

The price could be right for these stocks.

3 Magnificent Stocks Under $100 to Buy in November

SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.

Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales

Carvana

NVIDIA

Should you add these fast-growing stocks to your portfolio?

3 Stocks That Have Generated 1,000% Returns in Just 2 Years

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and CEO Maky Zanganeh - CEO and President Manmeet Soni - COO and CFO Allen Yang - Chief Medical Officer Conference Call Participants Mitchell Kapoor - H. C. Wainwright Brad Canino - Stifel Yigal Nochomovitz - Citi Operator Good morning.

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter and nine months ended September 30, 2024. Operational & Corporate Updates Our operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects.

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

The potential upside of this stock is undeniably meaty.

Is Summit Therapeutics a Millionaire Maker?

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?

This drugmaker's lead candidate could become a top-selling cancer therapy.

News for Summit Therapeutics Stock (SMMT)